Seoul School of Integrated Sciences and Technologies

2 Day Digi-Tech Pharma & AI (Artificial Intelligence) Conference 2023: Explore the Novel Technologies and Developments Reforming the Pharmaceutical Industry (London, United Kingdom - May 10-11, 2023)

Retrieved on: 
Thursday, April 13, 2023
Data management, Informatics, Science, Blockchain, Partnership, Data science, Sachem Head Capital Management, Internet of things, Value, Deep learning, Medication, Intelligence, Genomics, Seoul School of Integrated Sciences and Technologies, Cloud computing, GMS, Digital health, Machine learning, Management, Medicine, Pleasure, Drug discovery, VPS, Virtual reality, Artificial intelligence, Clinical, AI, ChromeOS, Pharmaceutical industry, Fine chemical

DUBLIN, April 13, 2023 /PRNewswire/ -- The "Digi-Tech Pharma & AI 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 13, 2023 /PRNewswire/ -- The "Digi-Tech Pharma & AI 2023" conference has been added to ResearchAndMarkets.com's offering.
  • The 6th Annual Digi-Tech Pharma & AI conference brings with it even more interactive sessions, expert speakers, senior professionals and decision-makers from leading pharma, biotech and healthcare industries.
  • This event is designed for senior-level attendees from various companies including pharmaceutical, biotechnological, biopharmaceutical, CROs, Diagnostics, solution providers and government institutions.
  • It gives us great pleasure in welcoming you to our whole new pharmaceutical technology conference 6th Annual Digi-Tech Pharma & AI 2023.

VMD Corp Promotes Gregg Leone to Chief Growth Officer

Retrieved on: 
Monday, May 9, 2022
Strategic planning, Trust, United States Department of State, Seoul School of Integrated Sciences and Technologies, Department, Federal, Unitary state, Justice, James Madison University, Business development, Leadership, Government, Rois, VMD, United States Secretary of Homeland Security, Marketing, Department of Justice (Canada), Federation, Bachelor of Science in Information Technology, CACI, Technology, Executive, Growth, Multimedia, Management

FAIRFAX, Va., May 9, 2022 /PRNewswire/ -- VMD Corp, a leading provider of cybersecurity, agile engineering, and critical infrastructure protection to the U.S. Federal Government, today announced that it has promoted former Executive Vice President of Business Development Gregg Leone to the newly created role of Chief Growth Officer, effective immediately.

Key Points: 
  • FAIRFAX, Va., May 9, 2022 /PRNewswire/ -- VMD Corp, a leading provider of cybersecurity, agile engineering, and critical infrastructure protection to the U.S. Federal Government, today announced that it has promoted former Executive Vice President of Business Development Gregg Leone to the newly created role of Chief Growth Officer, effective immediately.
  • "Since joining VMD five years ago, Gregg has been instrumental in our growth helping us go from a small to a mid-sized contractor while also deepening our customer and partner relationships and helping us to attract top talent," VMD Chief Executive Officer Deepti Malhotra said.
  • Leone has more than 20 years of government IT contracting experience with particular expertise in leadership, strategy, and portfolio management.
  • Gregg will also be responsible for ensuring and managing VMD's growth through metrics like revenue, social ROIs, and employee engagement.

Novo Integrated Sciences’ subsidiary, Novo Healthnet Limited, and EK-Tech Solutions Announce Joint Venture for Enhanced Telehealth Platform

Retrieved on: 
Thursday, October 14, 2021
Health, Technology, Practice Management, Audio, Video, Telecommunications, Mobile, Wireless, Software, Telehealth, JV, Acceleration, Technology, Diagnosis, Solution, Seoul School of Integrated Sciences and Technologies, Population, Therapy, NHL, Patient, Science, CEO, Health, NASDAQ, Novo, Medical imaging, Pharmaceutical industry, Healthcare

MiTelemed+, through the iTelemed platform, allows Novo to offer the patient and the practitioner a sophisticated and enhanced telehealth interaction.

Key Points: 
  • MiTelemed+, through the iTelemed platform, allows Novo to offer the patient and the practitioner a sophisticated and enhanced telehealth interaction.
  • To date, telehealth technology usage is one dimensional and limiting in comfort for practitioners to provide in-depth diagnosis and treatment solutions.
  • Through our JV with EK-Tech, MiTelemed+ offers the next generation of telehealth technology capability.
  • Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation.

Novo Integrated Sciences to Present at the Benzinga Virtual Global Healthcare Small Cap Conference on September 30th

Retrieved on: 
Thursday, September 23, 2021
Alternative Medicine, General Health, Health, Physical Therapy, Health, Solution, Therapy, Conference, NASDAQ, Patient, NHL, Population, CEO, Science, Technology, Novo, Seoul School of Integrated Sciences and Technologies, Acceleration, Healthcare

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced that Robert Mattacchione, Chairman and CEO, is scheduled to present at the Benzinga Virtual Global Healthcare Small Cap Conference.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced that Robert Mattacchione, Chairman and CEO, is scheduled to present at the Benzinga Virtual Global Healthcare Small Cap Conference.
  • ET
    The Novo management team will be available for one-on-one meetings for the duration of the conference.
  • To schedule a meeting or for more information on the conference, please contact your Benzinga representative, or Chris David, COO-President, at [email protected] .
  • Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation.

Novo Integrated Sciences Signs LOIs to Acquire Seven Pharmacies in the United States

Retrieved on: 
Monday, August 30, 2021
Alternative Medicine, Communications, Health, General Health, Pharmaceutical, Public Relations, Investor Relations, Population, Novo, Therapy, Acquisition, Science, Pharmacy, Seoul School of Integrated Sciences and Technologies, NASDAQ, Acceleration, Patient, Solution, CEO, NHL, Technology, Health, Healthcare

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo), a pioneer with a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the signing of non-binding Letters of Intent (LOI) to acquire seven pharmacies in the United States.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the Company or Novo), a pioneer with a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the signing of non-binding Letters of Intent (LOI) to acquire seven pharmacies in the United States.
  • The proposed all-stock transactions contemplate the acquisition, by Novo, of a 50% interest in each pharmacy.
  • Novo expects to negotiate and enter into definitive agreements and to close the acquisitions during the second half of 2021.
  • Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation.